Goldman Sachs’s Aethlon Medical AEMD Stock Holding History

Goldman Sachs’s Portfolio AEMD Stock Details AEMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-18	Closed	-$3.92K	–	5886
2022 Q4	$3.92K	Buy	+18	New	+$6.56K	﹤0.01%	5828
2019 Q3	–	Sell	-1	Closed	-$4K	–	5142
2019 Q2	$4K	Buy	+1	New	+$6.7K	﹤0.01%	5091

Other funds holding AEMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AFGAS

Allegiance Financial Group Advisory Services Vienna, Virginia $578M AUM 24.83% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs's AEMD Position: Q1 2023 in Review

Goldman Sachs sold out of Aethlon Medical (AEMD) in Q1 2023, closing a stake of 18 shares — an estimated $3.92K sold.

Goldman Sachs first reported a position in AEMD in Q2 2019 and held it in 2 quarters. The position peaked at $4K in Q2 2019. 23 funds tracked by Wall St. Rank hold AEMD as of Q1 2023.

Goldman Sachs reported no remaining Aethlon Medical position as of Q1 2023 after selling out during the quarter.
Goldman Sachs sold 18 Aethlon Medical shares in Q1 2023, an estimated $3.92K.
Goldman Sachs first reported a position in Aethlon Medical in Q2 2019 and held it in 2 quarters.
Goldman Sachs's Aethlon Medical position peaked at $4K in Q2 2019.
23 funds tracked by Wall St. Rank held Aethlon Medical as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.